Blood Targets of Adjuvant Drugs Against COVID19

• Main Authors: Di Micco P, Di Micco G, Russo V, Poggiano MR, Salzano C, Bosevski M, Imparato M, Fontanella L, Fontanella A
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-07-01
• Series: Journal of Blood Medicine
• Subjects: covid19; flavonoid; heparin; ace-inhibitors; interluekin; angiotensin receptor blockers
• Online Access: https://www.dovepress.com/blood-targets-of-adjuvant-drugs-against-covid19-peer-reviewed-article-JBM

Pierpaolo Di Micco,1 Gianluca Di Micco,2 Vincenzo Russo,3 Maria Rita Poggiano,1 Ciro Salzano,1 Marijan Bosevski,4 Michele Imparato,1 Luca Fontanella,1 Andrea Fontanella1 1Internal Medicine Department, Emergency Room Unit, Fatebenefratelli Hospital of Naples, Naples, Italy; 2Centro Diagnostico Varelli, Naples, Italy; 3University Cardiology Clinic, Faculty of Medicine, Skopje, Macedonia; 4Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli” Monaldi Hospital, Naples 80131, ItalyCorrespondence: Pierpaolo Di Micco Email [e-mail]: While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-known drugs such as anticoagulants, antihypertensives, antiserotoninergics and immunomodulants. We here report a basic list of these drugs that include bioflavonoids, heparinoids, ACE inhibitors, angiotensin receptor blockers, antiserotoninergics, and monoclonal antibodies against cytokines that may interact with the viral cycle.Keywords: COVID19, flavonoid, heparin, ace-inhibitors, interleukin, angiotensin receptor blockers